PCN39 Cost-Effectiveness of Brentuximab Vedotin for Relapsed or Refractory Systemic Anaplastic Large-CELL Lymphoma in China

Abstract

Authors

L. Zheng W. Zhang W. Xu L.H. Chuang W. Sun

Full Text Cite This Article
Back to Volume 22, Supplemental S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×